sb 203580 has been researched along with riboflavin in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (riboflavin) | Trials (riboflavin) | Recent Studies (post-2010) (riboflavin) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 9,345 | 389 | 3,015 |
Protein | Taxonomy | sb 203580 (IC50) | riboflavin (IC50) |
---|---|---|---|
Thiosulfate sulfurtransferase | Homo sapiens (human) | 8.8 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, Z; Culibrk, B; Devine, DV; Schubert, P | 1 |
1 other study(ies) available for sb 203580 and riboflavin
Article | Year |
---|---|
p38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treatment.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Blood Platelets; Caspase 3; Caspase 9; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Photosensitizing Agents; Protein Kinase Inhibitors; Protein Kinases; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Pyridines; Riboflavin; Signal Transduction; Ultraviolet Rays | 2015 |